InMed Pharmaceuticals Inc. cash flow to debt ratio of -769.07% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

InMed Pharmaceuticals Inc.'s free cash flow has decreased 11.03% from $-7.00M last year to $-7.77M, signaling decreasing performance

InMed Pharmaceuticals Inc.'s debt to equity ratio is 0.06, which means that the company's assets are healthy financed, signaling financial stability.

InMed Pharmaceuticals Inc.'s debt has decreased relative to shareholder equity from 0.10 last year to 0.06 today, signaling strengthened financials

InMed Pharmaceuticals Inc. has a net cash position, so leverage is healthy.

InMed Pharmaceuticals Inc.'s interest coverage ratio is -496.36, which means that the company struggles to meet interest obligations, signaling financial risk.

InMed Pharmaceuticals Inc.'s profit margin has decreased (47.60%) in the last year from -166.94% to -246.41%, signaling decreasing performance

InMed Pharmaceuticals Inc.'s short-term assets of $17.53M exceed its short-term liabilities of $2.51M

InMed Pharmaceuticals Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

InMed Pharmaceuticals Inc.'s return on equity of -72.72%, is lower than 15.00%, indicating bad performance

InMed Pharmaceuticals Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

InMed Pharmaceuticals Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

InMed Pharmaceuticals Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

InMed Pharmaceuticals Inc. has negative free cash flow, indicating cash burn

InMed Pharmaceuticals Inc.'s yearly earnings has decreased 6.34% since last year from $-7.68M to $-8.16M, signaling decreasing performance

InMed Pharmaceuticals Inc.'s yearly revenue has decreased 21.41% since last year from $6.29M to $4.94M, signaling decreasing performance

ROIC -135.77% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

InMed Pharmaceuticals Inc.'s 3-year revenue CAGR of 65.55% is positive, indicating growing revenue over the past 3 years

InMed Pharmaceuticals Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

InMed Pharmaceuticals Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

InMed Pharmaceuticals Inc. has insufficient data to evaluate this check.

InMed Pharmaceuticals Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

InMed Pharmaceuticals Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

InMed Pharmaceuticals Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

InMed Pharmaceuticals Inc. has insufficient data to evaluate this check.

InMed Pharmaceuticals Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

InMed Pharmaceuticals Inc. has a price-to-book ratio of 0.83x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

InMed Pharmaceuticals Inc. has a price-to-sales ratio of 1.42x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue